IDNT
2001
Irbesartan Diabetic Nephropathy Trial
In 1,715 patients with type 2 diabetes and nephropathy, irbesartan reduced progression of the renal composite compared with amlodipine or placebo.
Result
Primary endpoint: Doubling of creatinine, ESRD or death
Irbesartan vs placebo HR 0.80 (p=0.02); vs amlodipine HR 0.77 (p=0.006).
- Subtopic
- RAAS blockade
- Design
- Double-blind RCT, three arms
- Relevance
- Practice-defining: a trial the guidelines cite as evidence.
- Source
- Lewis EJ, et al. N Engl J Med. 2001;345(12):851-860.doi 10.1056/NEJMoa011303
Discussion & critique
Showed renoprotection is independent of the calcium-channel-blocker comparator and of the blood-pressure effect.